Pi MZ and COPD: will we ever know? | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Responses

Editorial

Pi MZ and COPD: will we ever know?

Free

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

No

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

Authors' reply
Niels Seersholm
Published on: 19 November 2004
"MZ Alpha1-Antitrypsin Genotype Unaffected by Age"
Morten Dahl
Published on: 2 November 2004

Published on: 19 November 2004
Authors' reply
- Niels Seersholm, Consultant
Dear Editor
Morten Dahl and Børge G. Nordestgaard argue against selection bias, if genotyping is performed after lung function tests because a newborn with PiMZ genotype does not change to PiZZ later in life. The latter is obviously true and not the issue. The reason for possible selection bias is that some persons may fail to have genotype performed due to a characteristic of the lung function tests under stud...
Show More

Dear Editor
Morten Dahl and Børge G. Nordestgaard argue against selection bias, if genotyping is performed after lung function tests because a newborn with PiMZ genotype does not change to PiZZ later in life. The latter is obviously true and not the issue. The reason for possible selection bias is that some persons may fail to have genotype performed due to a characteristic of the lung function tests under study and this may affect the result of a longitudinal study.
If we assume that PiMZ persons have a very fast FEV1 decline with premature death, a number of PiMZ persons may have attended the first examinations, but did not live long enough to show up to the last visit with genotyping. These persons would not be included in the analysis of FEV1 decline and the result would be an underestimate of FEV1 decline with the possible conclusion that PiMZ is not a risk factor for lung disease. This is usually called a survivor effect.
The opposite may also be true. Suppose a reverse relationship between pulmonary function and compliance to study visits, that is persons with normal FEV1, normal FEV1 decline, and no lung symptoms may not show up to the last visit because they feel well. This would tend to exaggerate any increased decline in FEV1 and the conclusion could be that PiMZ is an important risk factor for lung disease.
These are just two of many examples of possible biases. They show that even if the risk factor (PiMZ) is present from birth, it is vital to postpone the collection of tests for analysis after genotyping has been performed.
Show Less

Conflict of Interest:
None declared.
- Back to top
Published on: 2 November 2004
"MZ Alpha1-Antitrypsin Genotype Unaffected by Age"
- Morten Dahl
Dear Editor
In a recent otherwise excellent editorial in Thorax [1], Dr. Seersholm indicated that our previous results on FEV1 decline based on the Copenhagen City Heart Study [2] are biased. We disagree, and rather believe that our study of the general population is prone to less bias than case-control or family-based studies.
Dr. Seersholm argues that because we genotyped study participants after measuremen...
Show More

Dear Editor
In a recent otherwise excellent editorial in Thorax [1], Dr. Seersholm indicated that our previous results on FEV1 decline based on the Copenhagen City Heart Study [2] are biased. We disagree, and rather believe that our study of the general population is prone to less bias than case-control or family-based studies.
Dr. Seersholm argues that because we genotyped study participants after measurement of FEV1 in 1976-1978, 1981-1984, and 1991-1994, our results are biased [1]. Certainly, if conventional risk factors are measured after development of disease, the disease might be the cause of the risk factor, rather than vice versa. However, an alpha1-antitrypsin MZ genotype in a newborn does not change into a ZZ genotype by age. Therefore, Pi MZ genotype preceded FEV1 outcomes in our study, even though genotypes were determined after FEV1 measurements. Using identical logic, genotype preceded outcomes in a similar manner in other previous studies [3-6].
Selection bias could potentially be a reason for discrepancies between studies on Pi MZ and COPD [1,7]. In our study where genotype distribution was in Hardy Weinberg equilibrium, we found no evidence for selection against any alpha1-antitrypsin genotype [2,8]. Therefore, as also pointed out by Dr. Seersholm [1], selection bias is more likely in case-control and family-based studies than in cohort studies of the general population.
Morten Dahl and Børge G. Nordestgaard. Dept of Clinical Biochemistry, Herlev University Hospital, Copenhagen, Denmark.
References
(1) Seersholm N. Pi MZ and COPD: will we ever know? Thorax 2004;59:823-825.
(2) Dahl M, Tybjærg-Hansen A, Lange P, Vestbo J, Nordestgaard BG.Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes. A longitudinal study of the general population. Ann Intern Med 2002;136:270-279.
(3) Juul K, Tybjærg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002;100:3-10.
(4) Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Integrin beta3Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 2003;95:1150-1157.
(5) Dahl M, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. A population -based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004;199:1391-1399.
(6) Wadsworth MEJ, Vinall LE, Jones AL, Hardy RJ, Whitehouse DB, Butterworth SL, Hilder WS, Lovegrove JU, Swallow DM. Alpha-1-antitrypsin as a risk factor for infant and adult respiratory outcomes in a national birth cohort. Am J Respir Cell Mol Biol (in press).
(7) Hersh CP, Dahl M, Ly CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004;59:843-849.
(8) Dahl M, Tybjærg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha1-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003;107:747-752.
Show Less

Conflict of Interest:
None declared.
- Back to top